Literature DB >> 29605153

Time to Reimplantation: Waiting Longer Confers No Added Benefit.

Arash Aali Rezaie1, Karan Goswami1, Noam Shohat1, Anthony T Tokarski1, Alexander E White2, Javad Parvizi1.   

Abstract

BACKGROUND: While the preferred surgical treatment for chronic periprosthetic joint infection (PJI) in North America is a 2-stage exchange arthroplasty, the optimal time between first-stage and reimplantation surgery remains unknown. This study was conceived to examine the association between time to reimplantation and treatment failure.
METHODS: Using an institutional database, we identified PJI cases treated with 2-stage exchange arthroplasty between 2000 and 2016. Musculoskeletal Infection Society criteria were used to define PJI, and treatment failure was defined using Delphi criteria. The interstage interval between first-stage and reimplantation surgery for each case was collected, alongside demographics, patient-related and organism-specific data. Multivariate logistic regression analyses were used to examine association with treatment failure.
RESULTS: Our final analysis consisted of 282 patients with an average time to reimplantation of 100.2 days (range, 20-648). Sixty-three patients (22.3%) failed at 1 year based on Delphi criteria. Time to reimplantation was not significantly associated with failure in both univariate (P = .598) and multivariate (P = .397) models. However, patients reimplanted at >26 weeks were twice as likely to fail in comparison to those reimplanted within <26 weeks (43.8% vs 21.1%), and this finding reached marginal significance (P = .057). Patients who failed had significantly more comorbidities (P = .008). Charlson comorbidity index was the only variable significantly associated with treatment failure in regression analysis (odds ratio, 1.40; 95% confidence interval, 1.06-1.86; P = .019).
CONCLUSION: The length of the interstage interval was not a statistically significant predictor of failure in patients undergoing 2-stage exchange arthroplasty for PJI.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2-stage exchange arthroplasty; cement spacer; failure; periprosthetic joint infection; reimplantation; revision joint arthroplasty

Mesh:

Year:  2018        PMID: 29605153     DOI: 10.1016/j.arth.2018.01.073

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  6 in total

1.  Factors associated with infection recurrence after two-stage exchange for periprosthetic hip infection.

Authors:  Fabian Schwolow; Bernd Füchtmeier; Franz Müller
Journal:  Int Orthop       Date:  2022-02-07       Impact factor: 3.075

2.  Synovial Cell Count Before Reimplantation Can Predict the Outcome of Patients with Periprosthetic Knee Infections Undergoing Two-stage Exchange.

Authors:  Tiziana Ascione; Giovanni Balato; Massimo Mariconda; Francesco Smeraglia; Andrea Baldini; Cristiano De Franco; Giuseppe Pandolfo; Roberta Siciliano; Pasquale Pagliano
Journal:  Clin Orthop Relat Res       Date:  2021-09-01       Impact factor: 4.755

3.  Tissue-level cytokines in a rodent model of chronic implant-associated infection.

Authors:  Nicole Prince; Julia A Penatzer; Taylor L Shackleford; Elizabeth K Stewart; Matthew J Dietz; Jonathan W Boyd
Journal:  J Orthop Res       Date:  2020-12-15       Impact factor: 3.102

4.  Predicting Success of Two-Stage Exchange for Prosthetic Joint Infection Using C-Reactive Protein/Albumin Ratio.

Authors:  Cierra S Hong; Sean P Ryan; Jonathan A Gabor; Michael A Bergen; Ran Schwarzkopf; Thorsten M Seyler
Journal:  Adv Orthop       Date:  2019-05-02

5.  [Research progress of two-stage revision for periprosthetic joint infection after hip and knee arthroplasties].

Authors:  Xiangxuan Wang; Wenming Zhang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-12-15

6.  When Total Joint Arthroplasty After Septic Arthritis Can Be Safely Performed.

Authors:  Timothy L Tan; Chi Xu; Feng-Chih Kuo; Elie Ghanem; Jaiben George; Noam Shohat; Ji-Ying Chen; Mel S Lee; Carlos Higuera; Javad Parvizi
Journal:  JB JS Open Access       Date:  2021-05-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.